Healthline: Rates of IBD including Crohn’s Disease are three times higher than realized
UC digestive diseases expert discusses treatment options
A journalist for Healthline spoke with Loren Brook, MD, an assistant professor in the UC Department of Internal Medicine, about possible treatments for inflammatory bowel disease (IBD). In 2015, more than 3 million U.S. adults reported a diagnosis of IBD, an ongoing inflammation of all or part of the digestive tract, and includes two conditions, Crohn’s Disease and ulcerative colitis.
Brook, also a UC Health physician, explained the disease is usually lifelong but can be managed with relatively minor anti-inflammatory drugs such as oral mesalamine to immune-suppressing medications such as Remicade or steroids.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.
Combination immunotherapy helps overcome melanoma treatment resistance
November 10, 2025
MSN highlighted research led by the University of Cincinnati Cancer Center's Trisha Wise-Draper showing a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.